Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A

Full text
Author(s):
Show less -
Castro, Julia T. [1] ; Oliveira, Giuliana S. [1] ; Nishigasako, Melissa A. [1] ; Debrie, Anne-Sophie [2] ; Miyaji, Eliane N. [1] ; Soares-Schanoski, Alessandra [1] ; Akamatsu, Milena A. [3] ; Locht, Camille [2] ; Ho, Paulo L. [3] ; Mielcarek, Nathalie [2] ; Oliveira, Maria Leonor S. [1]
Total Authors: 11
Affiliation:
[1] Inst Butantan, Lab Bacteriol, Sao Paulo, SP - Brazil
[2] Univ Lille, Inst Pasteur Lille, CIIL Ctr Infect & Immun Lille, CNRS, INSERM, CHU Lille, U1019, UMR 8204, Lille - France
[3] Inst Butantan, Secao Vacinas Aerob, Div Bioind, Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: PLoS One; v. 15, n. 1 JAN 16 2020.
Web of Science Citations: 1
Abstract

Pneumococcal Surface Protein A (PspA) has been successfully tested as vaccine candidate against Streptococcus pneumoniae infections. Vaccines able to induce PspA-specific antibodies and Th1 cytokines usually provide protection in mice. We have shown that the whole cell pertussis vaccine (wP) or components from acellular pertussis vaccines, such as Pertussis Toxin or Filamentous Hemagglutinin (FHA), are good adjuvants to PspA, suggesting that combined pertussis-PspA vaccines would be interesting strategies against the two infections. Here, we evaluated the potential of wP as a delivery vector to PspA. Bordetella pertussis strains producing a PspA from clade 4 (PspA4Pro) fused to the N-terminal region of FHA (Fha44) were constructed and inactivated with formaldehyde for the production of wP(PspA4Pro). Subcutaneous immunization of mice with wP(PspA4Pro) induced low levels of anti-PspA4 IgG, even after 3 doses, and did not protect against a lethal pneumococcal challenge. Prime-boost strategies using wP(PspA4Pro) and PspA4Pro showed that there was no advantage in using the wP(PspA4Pro) vaccine. Immunization of mice with purified PspA4Pro induced higher levels of antibodies and protection against pneumococcal infection than the prime-boost strategies. Finally, purified Fha44:PspA4Pro induced high levels of anti-PspA4-Pro IgG, but no protection, suggesting that the antibodies induced by the fusion protein were not directed to protective epitopes. (AU)

FAPESP's process: 16/17258-9 - Bordetella pertussis and its components as delivery systems and adjuvants for vaccine development against Streptococcus pneumoniae
Grantee:Júlia Tavares de Castro
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 17/01992-8 - Adjuvant activity of the filamentous hemagglutinin from Bordetella pertussis in fusion with the PspA antigen from Streptococcus pneumoniae
Grantee:Melissa Akemi Nishigasako
Support Opportunities: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 16/13134-3 - Recombinant Vaccines against Streptococcus pneumoniae and Bordetella pertussis
Grantee:Maria Leonor Sarno de Oliveira
Support Opportunities: Regular Research Grants